was read the article
array:25 [ "pii" => "S2013251416000298" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2016.02.008" "estado" => "S300" "fechaPublicacion" => "2016-03-01" "aid" => "125" "copyright" => "Sociedad Española de Nefrología" "copyrightAnyo" => "2015" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2016;36:156-63" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4339 "formatos" => array:3 [ "EPUB" => 305 "HTML" => 3370 "PDF" => 664 ] ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0211699515001927" "issn" => "02116995" "doi" => "10.1016/j.nefro.2015.10.007" "estado" => "S300" "fechaPublicacion" => "2016-03-01" "aid" => "125" "copyright" => "Sociedad Española de Nefrología" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2016;36:156-63" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7421 "formatos" => array:3 [ "EPUB" => 329 "HTML" => 6120 "PDF" => 972 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Reanálisis del estudio ESHOL: mortalidad por todas las causas considerando riesgos de competición y tiempo-dependientes para trasplante renal" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "156" "paginaFinal" => "163" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "ESHOL study reanalysis: All-cause mortality considered by competing risks and time-dependent covariates for renal transplantation" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figura 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2745 "Ancho" => 3341 "Tamanyo" => 449172 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Análisis de sensibilidad para el evento principal mostrando los <span class="elsevierStyleItalic">hazard ratio</span> (IC 95%) para la intervención basado en las variables relevantes que se encontraron predictores independientes para todas las causas de mortalidad.</p> <p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Multivariante I: edad, género, diabetes y acceso vascular.</p> <p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Multivariante II: edad, género, diabetes, acceso vascular e índice de comorbilidad de Charlson.</p> <p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Multivariante III: edad, género, diabetes, acceso vascular, índice de comorbilidad de Charlson y censura para trasplante renal.</p> <p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">1T, 2T y 3T: primer, segundo y tercer terciles.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Francisco Maduell, Francesc Moreso, Josep Mora-Macià, Mercedes Pons, Rosa Ramos, Jordi Carreras, Jordi Soler, Ferrán Torres" "autores" => array:9 [ 0 => array:2 [ "nombre" => "Francisco" "apellidos" => "Maduell" ] 1 => array:2 [ "nombre" => "Francesc" "apellidos" => "Moreso" ] 2 => array:2 [ "nombre" => "Josep" "apellidos" => "Mora-Macià" ] 3 => array:2 [ "nombre" => "Mercedes" "apellidos" => "Pons" ] 4 => array:2 [ "nombre" => "Rosa" "apellidos" => "Ramos" ] 5 => array:2 [ "nombre" => "Jordi" "apellidos" => "Carreras" ] 6 => array:2 [ "nombre" => "Jordi" "apellidos" => "Soler" ] 7 => array:2 [ "nombre" => "Ferrán" "apellidos" => "Torres" ] 8 => array:1 [ "colaborador" => "en nombre del grupo del estudio ESHOL" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2013251416000298" "doi" => "10.1016/j.nefroe.2016.02.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251416000298?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699515001927?idApp=UINPBA000064" "url" => "/02116995/0000003600000002/v3_201704120115/S0211699515001927/v3_201704120115/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2013251416000286" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2016.02.007" "estado" => "S300" "fechaPublicacion" => "2016-03-01" "aid" => "124" "copyright" => "Sociedad Española de Nefrología" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2016;36:164-75" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4650 "formatos" => array:3 [ "EPUB" => 298 "HTML" => 3694 "PDF" => 658 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "164" "paginaFinal" => "175" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Efectividad y persistencia de los tratamientos del hiperparatiroidismo secundario en pacientes incidentes en hemodialisis" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2262 "Ancho" => 3483 "Tamanyo" => 606025 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Selection of the study population.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Angel Luis Martín de Francisco, Iain Andrew Gillespie, Ioanna Gioni, Jürgen Floege, Florian Kronenberg, Daniele Marcelli, David Collins. Wheeler, Marc Froissart, Tilman Bernhard. Drueke" "autores" => array:10 [ 0 => array:2 [ "nombre" => "Angel Luis Martín" "apellidos" => "de Francisco" ] 1 => array:2 [ "nombre" => "Iain Andrew" "apellidos" => "Gillespie" ] 2 => array:2 [ "nombre" => "Ioanna" "apellidos" => "Gioni" ] 3 => array:2 [ "nombre" => "Jürgen" "apellidos" => "Floege" ] 4 => array:2 [ "nombre" => "Florian" "apellidos" => "Kronenberg" ] 5 => array:2 [ "nombre" => "Daniele" "apellidos" => "Marcelli" ] 6 => array:2 [ "nombre" => "David Collins." "apellidos" => "Wheeler" ] 7 => array:2 [ "nombre" => "Marc" "apellidos" => "Froissart" ] 8 => array:2 [ "nombre" => "Tilman Bernhard." "apellidos" => "Drueke" ] 9 => array:1 [ "colaborador" => "on behalf of the ARO Steering Committee Cllaborators" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251416000286?idApp=UINPBA000064" "url" => "/20132514/0000003600000002/v4_201703310238/S2013251416000286/v4_201703310238/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S2013251416300037" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2016.03.005" "estado" => "S300" "fechaPublicacion" => "2016-03-01" "aid" => "120" "copyright" => "Sociedad Española de Nefrología" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2016;36:149-55" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3993 "formatos" => array:3 [ "EPUB" => 285 "HTML" => 3099 "PDF" => 609 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "How should we analyze and present mortality in our patients?: a multicentre GCDP experience" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "149" "paginaFinal" => "155" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Cómo debemos analizar y describir la mortalidad de nuestros pacientes: experiencia del Grupo Centro Diálisis Peritoneal" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1541 "Ancho" => 2979 "Tamanyo" => 241184 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">(A) Cumulative incidence calculated by the Kaplan–Meier method. (B) Incidence. Cumulative mortality estimated using the method of multiple decrements. It shows the number of patients at risk at the bottom of the figure. Cumulative mortality through both methods is shown in the table.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Darío Janeiro, José Portolés, Paula Lopez-Sanchez, Fernando Tornero, Carmen Felipe, Inés Castellano, Maite Rivera, Jeanette Fernandez-Cusicanqui, Antonio Cirugeda, María José Fernandez-Reyes, José Ramón Rodriguez-Palomares, María Auxiliadora Bajo, Guadalupe Caparrós, Alberto Ortiz" "autores" => array:15 [ 0 => array:2 [ "nombre" => "Darío" "apellidos" => "Janeiro" ] 1 => array:2 [ "nombre" => "José" "apellidos" => "Portolés" ] 2 => array:2 [ "nombre" => "Paula" "apellidos" => "Lopez-Sanchez" ] 3 => array:2 [ "nombre" => "Fernando" "apellidos" => "Tornero" ] 4 => array:2 [ "nombre" => "Carmen" "apellidos" => "Felipe" ] 5 => array:2 [ "nombre" => "Inés" "apellidos" => "Castellano" ] 6 => array:2 [ "nombre" => "Maite" "apellidos" => "Rivera" ] 7 => array:2 [ "nombre" => "Jeanette" "apellidos" => "Fernandez-Cusicanqui" ] 8 => array:2 [ "nombre" => "Antonio" "apellidos" => "Cirugeda" ] 9 => array:2 [ "nombre" => "María José" "apellidos" => "Fernandez-Reyes" ] 10 => array:2 [ "nombre" => "José Ramón" "apellidos" => "Rodriguez-Palomares" ] 11 => array:2 [ "nombre" => "María Auxiliadora" "apellidos" => "Bajo" ] 12 => array:2 [ "nombre" => "Guadalupe" "apellidos" => "Caparrós" ] 13 => array:2 [ "nombre" => "Alberto" "apellidos" => "Ortiz" ] 14 => array:1 [ "colaborador" => "con la participación del Grupo Centro de Diálisis Peritoneal (GCDP) RedinRen" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0211699515001873" "doi" => "10.1016/j.nefro.2015.09.014" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699515001873?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251416300037?idApp=UINPBA000064" "url" => "/20132514/0000003600000002/v4_201703310238/S2013251416300037/v4_201703310238/en/main.assets" ] "en" => array:22 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "ESHOL study reanalysis: All-cause mortality considered by competing risks and time-dependent covariates for renal transplantation" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "156" "paginaFinal" => "163" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Francisco Maduell, Francesc Moreso, Josep Mora-Macià, Mercedes Pons, Rosa Ramos, Jordi Carreras, Jordi Soler, Ferrán Torres" "autores" => array:9 [ 0 => array:4 [ "nombre" => "Francisco" "apellidos" => "Maduell" "email" => array:1 [ 0 => "fmaduell@clinic.ub.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Francesc" "apellidos" => "Moreso" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Josep" "apellidos" => "Mora-Macià" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "Mercedes" "apellidos" => "Pons" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "Rosa" "apellidos" => "Ramos" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 5 => array:3 [ "nombre" => "Jordi" "apellidos" => "Carreras" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] 6 => array:3 [ "nombre" => "Jordi" "apellidos" => "Soler" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">g</span>" "identificador" => "aff0035" ] ] ] 7 => array:3 [ "nombre" => "Ferrán" "apellidos" => "Torres" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">h</span>" "identificador" => "aff0040" ] ] ] 8 => array:2 [ "colaborador" => "on behalf of the study group ESHOL" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">◊</span>" "identificador" => "fn1" ] ] ] ] "afiliaciones" => array:8 [ 0 => array:3 [ "entidad" => "Departamento Nefrología, Hospital Clínic, Barcelona, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Departamento Nefrología, Hospital Universitari Vall d’Hebron, Barcelona, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Fresenius Medical Care, Clínica de Granollers, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "CETIRSA, Barcelona, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Hospital San Antonio Abad, Vilanova i la Geltrú, Barcelona, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Diaverum Baix Llobregat, L’Hospitalet, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Fresenius Medical Care, Clínica de Reus, Spain" "etiqueta" => "g" "identificador" => "aff0035" ] 7 => array:3 [ "entidad" => "Unidad de Bioestadística, Escuela de Medicina, Universitat Autònoma de Barcelona, Biostatistics and Data Management Platform, IDIBAPS, Hospital Clínic, Barcelona, Spain" "etiqueta" => "h" "identificador" => "aff0040" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author</span>." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Reanálisis del estudio ESHOL: mortalidad por todas las causas considerando riesgos de competición y tiempo-dependientes para trasplante renal" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1113 "Ancho" => 1667 "Tamanyo" => 98336 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Kaplan–Meier curves for 36-month survival in competitive risks cumulative incidence of death (Gray's test, <span class="elsevierStyleItalic">P</span> value<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.006). HD denotes hemodialysis, and OL-HDF, on-line hemodiafiltration.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">The “On-Line Hemodiafiltration Survival Study” [<span class="elsevierStyleItalic">Estudio de Supervivencia de Hemodiafiltración On-Line’</span> (ESHOL)]<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">1</span></a> showed that high-efficiency post-dilution OL-HDF reduces all-cause mortality versus conventional hemodialysis (HD) in prevalent chronic dialysis patients. The inferential analysis of the main variable, time to occurrence of any event, defined as all-cause mortality (overall survival), was estimated from the unadjusted Cox model with no imputation by means of the log-rank test for the between-treatment comparison and hazard ratios (HR) with their 95% confidence intervals. The study provided a detailed description of the time and causes of censoring to rule out any potential biases. However, during the observation period, 355 patients prematurely finished the study and, according to the study design, all these patients were censored at the time of premature termination. Most studies conducted in hemodialysis patients (the Hemodialysis (HEMO) study,<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">2</span></a> the Membrane Permeability Outcome (MPO) study,<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">3</span></a> the Turkish HDF study<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">4</span></a>) have been performed with this method, given that a high percentage of patients could be excluded mainly due to renal transplantation.</p><p id="par0010" class="elsevierStylePara elsevierViewall">In randomized clinical trials (RCT), it is recommended that data be analyzed by an intention-to-treat (ITT) analysis, which compares outcomes according to the initial random allocation, regardless of which intervention the patients actually received. ITT is recommended as the method of choice for analysis in trials investigating the superiority of an intervention.<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">5–7</span></a> Among studies comparing OL-HDF with HD, only the CONTRAST study<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">8</span></a> used ITT to analyze the primary endpoint. This kind of analysis avoids various misleading artifacts that can arise in intervention research, such non-random attrition of participants from the study. Importantly, a non-ITT analysis may lose the benefits of randomization, as the groups may no longer be balanced with regard to factors influencing the outcome.<a class="elsevierStyleCrossRefs" href="#bib0155"><span class="elsevierStyleSup">9,10</span></a> In the ESHOL study,<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">1</span></a> 164 patients were censored in the HD arm and 191 patients in the OL-HDF arm. As expected, renal transplantation was the main cause of censoring (79 in the HD arm and 101 in the OL-HDF arm). In survival analysis conducted to analyze the risk of death in dialysis patients, renal transplantation is a well-known competing risk because, after transplantation, patients will no longer be on dialysis and, therefore, will not be at risk of dying on dialysis. In this setting, the competing event, i.e. kidney transplantation, hinders the occurrence of the event of interest. Different approaches have been proposed to overcome this difficulty, but the best option is to conduct a full ITT analysis after completion of follow-up for censored observations for any reason in order to evaluate the risk of death for censored observations from both arms of the trial.</p><p id="par0015" class="elsevierStylePara elsevierViewall">The aim of this study was to investigate the outcome of patients who discontinued the ESHOL study and to re-analyze survival data by using the ITT population with a 3-year follow-up. We also performed a sensitivity analysis using the ITT population. Finally, we analyzed our data, considering renal transplantation as a competing event to patient death.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Patients and methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">General methods and patients</span><p id="par0020" class="elsevierStylePara elsevierViewall">The design and methods of the ESHOL study have previously been reported.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">11</span></a> Briefly, the ESHOL study was a prospective, randomized, open-label clinical trial in patients with end-stage renal disease under hemodialysis in Catalonia (Spain). The registered protocol number is <a href="ctgov:NCT00694031">NCT00694031</a>.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">12</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">The primary objective was to assess the effect of postdilution OL-HDF compared with hemodialysis on all-cause mortality. The primary outcome variable was the time to the occurrence of death from any cause. Key secondary outcomes were cardiovascular mortality and other causes of mortality.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Study population</span><p id="par0030" class="elsevierStylePara elsevierViewall">The study population has been previously described.<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">1,11</span></a> Essentially, the inclusion criteria consisted of patients older than 18 years with end-stage renal disease receiving thrice-weekly standard hemodialysis for more than 3 months. Exclusion criteria were as follows: active systemic diseases, liver cirrhosis, malignancy, immunosuppressive therapy, inadequate dialysis dose (single pool Kt/V<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>1.3), single-needle dialysis and the use of temporary non-tunneled catheters.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Randomization and dialysis treatment parameters</span><p id="par0035" class="elsevierStylePara elsevierViewall">Patients were randomized 1:1 to continue on thrice weekly hemodialysis or to start OL-HDF 3 times a week. The length of the recruitment period was 16 months and the study was completed to provide a complete follow-up until patient death or 3 years for all surviving patients.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Treatment procedures</span><p id="par0040" class="elsevierStylePara elsevierViewall">Both OL-HDF and hemodialysis were performed with ultrapure dialysis fluids and the length of dialysis sessions in each treatment modality was not modified. For patients on postdilution OL-HDF, a minimum of 18<span class="elsevierStyleHsp" style=""></span>L/session of replacement volume was requested. Patients not receiving the allocated treatment modality for more than 2 consecutive months were withdrawn from the study.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Censored observations</span><p id="par0045" class="elsevierStylePara elsevierViewall">In the original study, patients were observed until each enrolled patient completed 3 years of follow-up, until premature termination, or until death. In the original study, 355 out of 906 patients (39.2%) with premature termination were censored before completing the 3-year follow-up. For the present study, the principal investigators at each participating center were contacted to provide information on survival status at 3 years for each censored observation. Each principal investigator contacted the renal transplant unit where patients received a kidney transplant or other hemodialysis facilities where the patients were receiving treatment from the time of censoring. The date and cause of death for each participating patient censored during the study were recorded to calculate patient survival in the ITT population.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Statistical analysis</span><p id="par0050" class="elsevierStylePara elsevierViewall">All-cause mortality, as well as cardiovascular death, cachexia, infection, tumors, sudden death and death from other causes were described by means of the Kaplan–Meier method. The log-rank test was used for hypothesis testing, and the hazard ratio and its 95% confidence interval (95% CI) were estimated from the unadjusted Cox model. Additional multivariate Cox regression sensitivity analyses were conducted with adjustment by age, gender, diabetes, the Charlson comorbidity index (the original scale and also excluding diabetes) and the type of vascular access. Time-dependent Cox analysis, which included the time of transplantation<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">13</span></a> as well as the cumulative incidence curves of progression in a competing risks framework, with transplantation without death as a competing event,<a class="elsevierStyleCrossRefs" href="#bib0180"><span class="elsevierStyleSup">14,15</span></a> were also assessed to check the robustness of the study results.</p><p id="par0055" class="elsevierStylePara elsevierViewall">Two-sided significance tests were used throughout, and a <span class="elsevierStyleItalic">P</span>-value of <0.05 was considered significant. All statistical analyses were performed using the SAS 9.2 statistical package.</p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Results</span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Outcome of censored observations</span><p id="par0060" class="elsevierStylePara elsevierViewall">Of 906 patients included in the randomization, 355 (39.18%) prematurely discontinued the study because of kidney transplantation (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>180, 19.87%), change of dialysis unit (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>58, 6.40%), organizational changes (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>33, 3.64%), withdrawal of consent (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>27, 2.98%), need for a temporary catheter (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>19, 2.10%), change of treatment (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>15, 1.66%) or other, non-predefined reasons (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>23, 2.54%). In the present analysis, a 3-year follow-up was completed for all these patients with a premature termination. At 3 years, 305 patients were alive, 47 patients had died and only 3 patients were censored prematurely on the last date when known to be alive. Thus, the mean follow-up was 2.6<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>0.8 years and the median observation time for censored patients was 3.0 years. Mortality after discontinuation of the study was similar in both groups: 4.04 per 100 patient-year in the HD arm and 5.27 per 100 patient-year in the OL-HDF arm. The causes of mortality in discontinued patients in each arm are described in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>. There were no significant differences in the death rate in the 2 arms of the trial according to the causes of patient discontinuation (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">All-cause mortality in the intention-to-treat population</span><p id="par0065" class="elsevierStylePara elsevierViewall">During the 3-year follow-up, 207 patients died on treatment and 47 patients died after discontinuation of the study; thus, 254 out of 906 patients died (28.03%) during follow-up, with a 3-year all-cause mortality rate of 24.78% and 31.33% in the OL-HDF and the HD groups, respectively. Kaplan–Meier survival curves with the ITT population with only 3 censored patients showed that patient survival was lower in patients allocated to the HD arm than in those allocated to OL-HDF arm (log-rank <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.031) (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). Univariate Cox regression analysis showed that patients allocated to the OL-HDF group had a 24% risk reduction (hazard ratio [95% CI]: 0.76 [0.59 to 0.98]; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.031) for mortality for any cause (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>). The main causes of death were cardiovascular diseases (42.5%) and infectious diseases (16.9%) and there were no significant differences between groups (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Sensitivity analysis</span><p id="par0070" class="elsevierStylePara elsevierViewall">Sensitivity analyses were performed on the basis of the following variables, which were found to be independent predictors for all-cause mortality: age, gender, diabetes, the Charlson comorbidity index and vascular access. These variables were included in 3 different multivariate analyses to assess the covariate-adjusted risk estimates for the intervention (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). When these covariates were included, the effect of treatment was on the verge of significance (model I). In model II, renal transplantation was added to model I as a time-dependent covariate and the adjusted risk estimate for the intervention was identical to model I. Finally, in model III, an adjusted risk estimate was done considering renal transplantation as the only cause for censoring. The treatment risk estimates were also calculated in all subgroups arising from these variables, using the original categories for nominal variables and tertiles for continuous variables. All hazard ratios were consistent for both types of analysis and the statistical tests for interaction were not significant (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). In this analysis, male and older (upper tertile of age) patients, as well as patients in the upper tertile of the Charlson comorbidity index, obtained significant benefit from the intervention.</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">All-cause mortality by time-dependent and competing risks for transplantation</span><p id="par0075" class="elsevierStylePara elsevierViewall">Since the underlying risk of death is known to change after transplantation, we modeled all-cause mortality taking into account the time of transplantation in a time-dependent approach. The time-dependent Cox analysis (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>) showed very similar results to the main analysis with a hazard ratio [95% CI] of 0.77 [0.60 to 0.99] (<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.043).</p><p id="par0080" class="elsevierStylePara elsevierViewall">Survival analysis was repeated to assess the consistency of the results by considering renal transplantation as a competing event and consequently death after transplantation was not considered. For the other patients discontinuing the study, complete follow-up until 3 years was considered and events occurring after discontinuation of the study were included. Survival curves for both treatment groups are shown in <a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>, confirming that patients allocated to OL-HDF group had a higher survival than patients allocated to the HD arm (Gray's test, <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.006).</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia></span></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Discussion</span><p id="par0085" class="elsevierStylePara elsevierViewall">In the present study, we conducted a new analysis of the ESHOL-study with the ITT population with a complete follow-up for 3 years after trial enrollment. In the previous study,<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">1</span></a> patients who were alive when they discontinued the study for any reason were censored at the time of withdrawal. As in other studies conducted in patients on hemodialysis, there was a high rate of censored observations before 3 years (39.2%) and the main reason for censoring was renal transplantation, accounting for more than 50% of cases. Additionally, the proportion of patients receiving a kidney transplant was slightly higher in the HDF-OL arm than in the HD arm (101 out of 456 patients versus 79 out of 450 patients), suggesting that, despite the randomized allocation of patients to both arms, there may have been an unbalanced risk between the 2 groups. In survival analyses, all subjects at risk of experiencing an event constitute the risk set. Standard survival analytical methods such as the Kaplan–Meier method assume that censoring is “independent”, this is, that patients who are censored at a certain time point should be representative of those still at risk (and, thus, in the risk set) at that time point. In the ESHOL study, we observed that censoring was not independent, since censored patients had a lower risk of death than those continuing in the trial (the risk set). These results could be expected in hemodialysis patients who were censored mainly because of renal transplantation, since it is well known that the risk of death decreases after renal transplantation in chronic hemodialysis patients. Nevertheless, according to the randomized design of the trial, the risk of death in censored patients in both arms of the trial was not different (4.04 per 100 patients-year in the HD arm and 5.27 per 100 patients-year in the HDF-OL arm).</p><p id="par0090" class="elsevierStylePara elsevierViewall">“Intention to treat” is a strategy to analyze randomized controlled trials comparing patients according to the initial random allocation. This is generally interpreted as including all patients, regardless of whether they actually satisfied the entry criteria, the treatment actually received, and subsequent withdrawal or deviation from the protocol. The ITT approach maintains treatment groups that are similar apart from random variation and allows for non-compliance and deviations from policy by clinicians.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">16</span></a> This approach characterizes the effectiveness of the intervention and offers information on the potential benefit observed in clinical practice. If an ITT analysis is not done, clinical effectiveness may be overestimated.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">17</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">In the ESHOL study, an ITT analysis was not originally planned since we expected a significant percentage of withdrawals (15% per year) and assumed that it would not affect the main conclusions of our study. Indeed, other studies conducted in hemodialysis patients to evaluate the benefit of different interventions were performed with a similar design. To overcome this limitation and to gain further insight into the effectiveness of our intervention, we decided to conduct the present study with a complete ITT analysis of the ESHOL study. In the univariate analysis of the present study, we were able to demonstrate that patients allocated to the OL-HDF arm had a significant 24% risk reduction of death compared with patients allocated to the HD arm. Importantly, the death rate was lower in this ITT population than in patients continuing under hemodialysis. Thus, this new analysis is less powered to detect a difference between groups. This loss of statistical power partly explains why, after adjustment for age, gender, diabetes, the Charlson comorbidity index and vascular access in the multivariate analysis, the 20% risk reduction was only on the threshold of significance (<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.086).</p><p id="par0100" class="elsevierStylePara elsevierViewall">Despite the usefulness of ITT analysis to analyze the ESHOL study, the main reason for withdrawal was renal transplantation. This is a classic example of competing risk in nephrology and, in this situation, it has been proposed that an alternative way to analyze data is by a proportional cause-specific hazards model with application of Cox regression analysis for each of the specific event types.<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">7</span></a> In each of these models, the competing events are treated as censored observations. We have also performed this analysis (model III of the sensitivity analysis) and we observed a statistically significant 25% reduction in the risk of death by adjusting for confounders in patients allocated to the OL-HDF arm. Finally, the results of the 2 approaches to assess the potential effect of transplantation on the results, the time-dependent Cox analysis and the competing events approach, both yielded similar results to that of the primary raw analysis and confirmed the positive conclusions of the trial.</p><p id="par0105" class="elsevierStylePara elsevierViewall">In the last year, 4 meta-analyses have been published that analyze the effect of convective against diffusive therapies.<a class="elsevierStyleCrossRefs" href="#bib0200"><span class="elsevierStyleSup">18–21</span></a> Susantitaphong et al.<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">18</span></a> evaluated randomized controlled trials comparing the effect of convective therapies including high-flux dialysis, hemofiltration or hemodiafiltration versus low-flux dialysis. The 3 other most recent meta-analyses<a class="elsevierStyleCrossRefs" href="#bib0205"><span class="elsevierStyleSup">19–21</span></a> that included all 3 RCT with mortality as the primary endpoint<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">1,4,8</span></a> to compare convective techniques versus low- or high-flux hemodialysis were positive in terms of survival, but the results were inconclusive, probably due to the disparity of criteria and confounding factors. Only the meta-analysis of the EuDial working group,<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">21</span></a> including only RCT comparing OL-HDF versus hemodialysis (hemofiltration and AFB were excluded) showed the superiority of OL-HDF to HD on overall and cardiovascular mortality. The discrepancies between these meta-analyses can be explained by the different research questions, different selection criteria of clinical trials and potential confounding factors (delivered dose of convective therapy, pre- or postdilution infusion or treatment modality). A revised definition of HDF was published by the EuDial group,<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">22</span></a> in which HDF is a blood purification therapy combining diffusive and convective solute transport using a high-flux membrane characterized by an ultrafiltration coefficient greater than 20<span class="elsevierStyleHsp" style=""></span>mL/h/mmHg/m<span class="elsevierStyleSup">2</span> and a sieving coefficient for β<span class="elsevierStyleInf">2</span>-microglobulin greater than 0.6; convective transport is achieved by an effective convection volume of at least 20% of the total blood volume processed. If these criteria were applied when selecting the RCT for inclusion in meta-analyses, none of the 4 published meta-analyses would meet them. It can therefore be questioned whether these meta-analyses are valid to answer the question of whether high-volume HDF improves survival compared with hemodialysis.</p><p id="par0110" class="elsevierStylePara elsevierViewall">In summary, the results of this reanalysis of the ESHOL trial confirm that high efficiency postdilution OL-HDF reduces all-cause mortality versus conventional hemodialysis in prevalent patients. These results are consistent independently of the statistical analysis employed. The original results observed in the ESHOL study, which censored patients discontinuing the study for any reason, were confirmed in the present study, which considered all-cause mortality in the ITT population without censures and also considered all-cause mortality by time-dependent and competing risks for transplantation.</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Conflicts of interest</span><p id="par0115" class="elsevierStylePara elsevierViewall">The authors have no conflicts of interest to declare.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:11 [ 0 => array:3 [ "identificador" => "xres822473" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusion" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec819319" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres822472" "titulo" => "Resumen" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Objetivos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Métodos" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Resultados" ] 4 => array:2 [ "identificador" => "abst0045" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec819318" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Patients and methods" "secciones" => array:6 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "General methods and patients" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Study population" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Randomization and dialysis treatment parameters" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Treatment procedures" ] 4 => array:2 [ "identificador" => "sec0035" "titulo" => "Censored observations" ] 5 => array:2 [ "identificador" => "sec0040" "titulo" => "Statistical analysis" ] ] ] 6 => array:3 [ "identificador" => "sec0045" "titulo" => "Results" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0050" "titulo" => "Outcome of censored observations" ] 1 => array:2 [ "identificador" => "sec0055" "titulo" => "All-cause mortality in the intention-to-treat population" ] 2 => array:2 [ "identificador" => "sec0060" "titulo" => "Sensitivity analysis" ] 3 => array:2 [ "identificador" => "sec0065" "titulo" => "All-cause mortality by time-dependent and competing risks for transplantation" ] ] ] 7 => array:2 [ "identificador" => "sec0070" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0075" "titulo" => "Conflicts of interest" ] 9 => array:2 [ "identificador" => "xack275989" "titulo" => "Acknowledgments" ] 10 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2015-06-15" "fechaAceptado" => "2015-10-05" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec819319" "palabras" => array:4 [ 0 => "Convective therapies" 1 => "Intention to treat" 2 => "On-line hemodiafiltration" 3 => "Survival" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec819318" "palabras" => array:4 [ 0 => "Terapias convectivas" 1 => "Intención de tratar" 2 => "Hemodiafiltración <span class="elsevierStyleItalic">on-line</span>" 3 => "Supervivencia" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Background</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The ESHOL study showed that post-dilution online hemodiafiltration (OL-HDF) reduces all-cause mortality versus hemodialysis. However, during the observation period, 355 patients prematurely completed the study and, according to the study design, these patients were censored at the time of premature termination.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">The aim of this study was to investigate the outcome of patients who discontinued the study.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">During follow-up, 207 patients died while under treatment and 47 patients died after discontinuation of the study. Compared with patients maintained on hemodialysis, those randomized to OL-HDF had lower all-cause mortality (12.4 versus 9.46 per 100 patient-years, hazard ratio and 95% CI: 0.76; [0.59 to 0.98], <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.031). For all-cause mortality by time-dependent covariates and competing risks for transplantation, the time-dependent Cox analysis showed very similar results to the main analysis with a hazard ratio of 0.77 (0.60 to 0.99, <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.043).</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusion</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">The results of this analysis of the ESHOL trial confirm that post-dilution OL-HDF reduces all-cause mortality versus hemodialysis in prevalent patients. The original results of the ESHOL study, which censored patients discontinuing the study for any reason, were confirmed in the present ITT population without censures and when all-cause mortality was considered by time-dependent and competing risks for transplantation.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusion" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Introducción</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">El estudio ESHOL ha demostrado que la hemodiafiltración <span class="elsevierStyleItalic">on line</span> (HDF-OL) posdilución reduce la mortalidad por todas las causas respecto a la hemodiálisis (HD) en pacientes prevalentes. Sin embargo, durante el periodo de observación, 355 pacientes finalizaron prematuramente el estudio, de acuerdo con el diseño del mismo. Estos pacientes fueron censurados en el momento de la finalización prematura.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Objetivos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">El objetivo de este estudio fue investigar los eventos de los pacientes que abandonaron el estudio.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Métodos</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Reanalizar los datos de supervivencia utilizando la población por intención de tratar en los 3 años de seguimiento. Los datos fueron analizados considerando también el trasplante renal como evento competitivo de la muerte del paciente.</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Resultados</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Durante el seguimiento, 207 pacientes fallecieron durante el tratamiento y 47 después de abandonar el estudio. Comparados con aquellos pacientes que se mantuvieron en HD, los que fueron aleatorizados a HDF-OL tuvieron una mortalidad total menor (12,4 vs. 9,46 por 100/pacientes/año, <span class="elsevierStyleItalic">hazard ratio</span> [HR] e IC 95%: 0,76 [0,59-0,98]; p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,031). La mortalidad total por todas las causas, teniendo en consideración el riesgo competitivo del trasplante renal y tiempo-dependiente, mostró en el análisis de Cox tiempo-dependiente resultados similares al análisis principal con un HR de 0,77 (0,60-0,99; p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,043).</p></span> <span id="abst0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Conclusiones</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Los resultados del reanálisis del estudio ESHOL se confirman cuando se aplica el análisis en la población por intención de tratar sin censurar ninguna observación y considerando la mortalidad por todas las causas dependiente del tiempo y del riesgo competitivo del trasplante renal.</p></span>" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Objetivos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Métodos" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Resultados" ] 4 => array:2 [ "identificador" => "abst0045" "titulo" => "Conclusiones" ] ] ] ] "NotaPie" => array:2 [ 0 => array:3 [ "etiqueta" => "◊" "nota" => "<p class="elsevierStyleNotepara" id="npar0025">The institutions and investigators in the study group are listed in the <a class="elsevierStyleCrossRef" href="#sec0080">appendix</a>.</p>" "identificador" => "fn1" ] 1 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Please cite this article as: Maduell F, Moreso F, Mora-Macià J, Pons M, Ramos R, Carreras J, et al. Reanálisis del estudio ESHOL: mortalidad por todas las causas considerando riesgos de competición y tiempo-dependientes para trasplante renal. 2016;36:156–163.</p>" ] ] "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:3 [ "apendice" => "<p id="par0125" class="elsevierStylePara elsevierViewall">The following institutions and investigators participated in the ESHOL study:</p> <p id="par0130" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">CETIRSA, Barcelona</span>: M. Pons, B. Insensé, C. Perez, T. Feliz; <span class="elsevierStyleItalic">Hospital San Antonio Abad, Vilanova i la Geltru</span>: R. Ramos, M. Barbetta, C. Soto; <span class="elsevierStyleItalic">Fresenius Medical Care, Granollers</span>: J. Mora, A. Juan, O. Ibrik; <span class="elsevierStyleItalic">Diaverum Baix Llobregat, Hospitalet</span>: A. Foraster, J. Carreras; <span class="elsevierStyleItalic">Fresenius Medical Care, Hospitalet:</span> F. Moreso, M. Hueso, J. Nin, A. Fernández; <span class="elsevierStyleItalic">Fresenius Medical Care, Reus</span>: J. Soler, M. Arruche, C. Sánchez, J. Vidiella; <span class="elsevierStyleItalic">Fresenius Medical Care Diagonal, Barcelona</span>: F. Barbosa, M. Chiné, S. Hurtado; <span class="elsevierStyleItalic">CETIRSA, Terrassa</span>: J. Llibre, A. Ruiz, M. Serra, M. Salvó, T. Poyuelo; <span class="elsevierStyleItalic">Hospital Clínic, Barcelona</span>: F. Maduell, M. Carrera, N. Fontseré, M. Arias, Josep M Campistol,; <span class="elsevierStyleItalic">Fresenius Medical Care Julio Verne, Barcelona</span>: A. Merín, L. Ribera; <span class="elsevierStyleItalic">Fundació Althaia, Manresa</span>: JM. Galceran, J. Mòdol, E. Moliner, A. Ramirez; <span class="elsevierStyleItalic">Hospital Santa Tecla, Tarragona</span>: J. Aguilera, M. Alvarez; <span class="elsevierStyleItalic">Diaverum Bonanova, Barcelona</span>: B. de la Torre, M. Molera; <span class="elsevierStyleItalic">Diaverum IHB, Barcelona</span>: J. Casellas, G. Martín; <span class="elsevierStyleItalic">Fundació Puigvert, Barcelona</span>: E. Andres, E. Coll; <span class="elsevierStyleItalic">Hospital Josep Trueta, Girona</span>: M. Valles, C. Martínez; <span class="elsevierStyleItalic">Hospital General, Vic</span>: E. Castellote; <span class="elsevierStyleItalic">Diaverum, Mataró</span>: JM. Casals, J. Gabàs, M. Romero; <span class="elsevierStyleItalic">Hospital Universitari Bellvitge, Hospitalet</span>: A. Martinez-Castelao, X. Fulladosa; <span class="elsevierStyleItalic">Hospital de Terrassa</span>: M. Ramirez-Arellano, M Fulquet; <span class="elsevierStyleItalic">Diaverum Verge de Montserrat, Santa Coloma</span>: A. Pelegrí, M. el Manouari, N. Ramos; Centre <span class="elsevierStyleItalic">Secretari Coloma, Barcelona</span>: J. Bartolomé; <span class="elsevierStyleItalic">Hospital de Figueres</span>, R. Sans; <span class="elsevierStyleItalic">Hospital Arnau de Vilanova, Lleida</span>: E. Fernández, F. Sarró; <span class="elsevierStyleItalic">Hospital Santa Creu, Tortosa:</span> T. Compte; <span class="elsevierStyleItalic">Diaverum Nephros, Barcelona</span>: F. Marco, R. Mauri; <span class="elsevierStyleItalic">Clínica Girona</span>: J. Bronsoms.</p> <p id="par0135" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Clinical Trials Unit</span>: JA. Arnaiz, H. Beleta, A. Pejenaute (UASP Farmacología Clínica, Hospital Clínic Barcelona).</p> <p id="par0140" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Statistical analysis</span>: F. Torres, J. Ríos and J. Lara (Biostatistics Unit, School of Medicine, Universitat Autònoma de Barcelona; Biostatistics and Data Management Platform, IDIBAPS, Hospital Clinic; Barcelona).</p>" "etiqueta" => "Appendix" "identificador" => "sec0080" ] ] ] ] "multimedia" => array:6 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1112 "Ancho" => 1664 "Tamanyo" => 99760 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Kaplan–Meier curves for 36-month survival in the intention-to-treat population (<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.031 by the log-rank test). HD denotes hemodialysis, and OL-HDF, on-line hemodiafiltration.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2744 "Ancho" => 3345 "Tamanyo" => 472692 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Sensitivity analyses for the main outcome showing hazard ratios [95% CI] for the intervention based on relevant variables that were found to be independent predictors for all-cause mortality. Multivariate I: age, gender, diabetes and vascular access. Multivariate II: age, gender, diabetes, vascular access and the Charlson comorbidity index. Multivariate III: age, gender, diabetes, vascular access, Charlson comorbidity index and censoring for transplantation. 1T, 2T and 3T: first, second and third tertiles.</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1113 "Ancho" => 1667 "Tamanyo" => 98336 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Kaplan–Meier curves for 36-month survival in competitive risks cumulative incidence of death (Gray's test, <span class="elsevierStyleItalic">P</span> value<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.006). HD denotes hemodialysis, and OL-HDF, on-line hemodiafiltration.</p>" ] ] 3 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">HD denotes hemodialysis, and OL-HDF on-line hemodiafiltration.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Outcome \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col">HD group (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>164)</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col">OL-HDF group (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>191)</th><th class="td" title="table-head " align="center" valign="top" scope="col">Hazard ratio [95% CI] \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col"><span class="elsevierStyleItalic">P</span> value<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</th></tr><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Patient-years at risk \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">470.6</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">531.8</th><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">No. of events \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">No. of events/100 patient-yr \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">No. of events \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">No. of events/100 patient-Yr \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleBold">Death from any cause</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4.04 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">28 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">5.27 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.38 [0.76 to 2.49] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.285 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Cardiovascular cause</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.28 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.88 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.78 [0.61 to 5.21] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.285 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Heart failure \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.43 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.44 [0.04 to 4.9] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.496 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Ischemic heart disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.56 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2.7 [0.28 to 26] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.369 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Mesenteric trombosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Stroke \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.43 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.94 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2.22 [0.43 to 11.47] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.326 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Dysrhythmia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Peripheral arteriopathy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.352 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Infection</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.06 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.06 [0.32 to 3.48] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.919 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Tumor</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.64 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.38 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.59 [0.10 to 3.52] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.557 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Sudden death</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.94 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.036 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Cachexia</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.43 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.38 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.91 [0.13 to 6.43] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.921 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Death from other causes</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.64 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.56 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.87 [0.18 to 4.32] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.868 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1383023.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "*" "nota" => "<p class="elsevierStyleNotepara" id="npar0005"><span class="elsevierStyleItalic">P</span> value by the log-rank test.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Mortality of the 355 patients that discontinued study.</p>" ] ] 4 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">HD denotes hemodialysis, and OL-HDF on-line hemodiafiltration.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Outcome \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col">HD group (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>164)</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col">OL-HDF group (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>191)</th><th class="td" title="table-head " align="center" valign="top" scope="col">Hazard ratio [95% CI] \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col"><span class="elsevierStyleItalic">P</span> value<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</th></tr><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Patient-years at risk \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">470.6</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">531.8</th><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">No. of events/<span class="elsevierStyleItalic">n</span> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">No. of events/100 patient-yr \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">No. of events/<span class="elsevierStyleItalic">n</span> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">No. of events/100 patient-yr \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Renal transplant \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2/79 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.43 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">9/101 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.69 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3.63 [0.78 to 16.79] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.078 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Change of HD center \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3/25 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.64 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">7/33 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.32 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2.70 [0.56 to 13.00] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.197 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Organizational changes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">6/20 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.28 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2/13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.38 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.50 [0.10 to 2.49] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.390 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Withdrawal of consent \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2/12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.43 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3/15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.56 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.35 [0.22 to 8.07] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.744 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Temporary catheter \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1/8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3/11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.56 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2.55 [0.26 to 24.62] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.401 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Change of treatment \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2/8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.43 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1/7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.55 [0.05 to 6.07] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.620 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Other reasons \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3/12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.64 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3/11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.56 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.17 [0.24 to 5.82] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.845 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1383024.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "*" "nota" => "<p class="elsevierStyleNotepara" id="npar0010"><span class="elsevierStyleItalic">P</span> value by the log-rank test.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Revison of deaths of patients that discontinued study in relation to discontinued cause.</p>" ] ] 5 => array:8 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at3" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">HD denotes hemodialysis, and OL-HDF on-line hemodiafiltration.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Outcome \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col">HD group (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>450)</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col">OL-HDF Group (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>456)</th><th class="td" title="table-head " align="center" valign="bottom" scope="col">Hazard ratio [95% CI] \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col"><span class="elsevierStyleItalic">P</span> value<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</th></tr><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Patient-years at risk \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">1138.0</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">1194.4</th><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">No. of events \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">No. of events/100 patient-yr \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">No. of events \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">No. of events/100 patient-yr \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleBold">Death from any cause</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">141 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">12.39 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">113 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">9.46 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.76 [0.59 to 0.98] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.031 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Cardiovascular cause</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">61 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">5.36 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">47 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3.93 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.73 [0.50 to 1.07] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.107 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Heart failure \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.05 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.67 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.63 [0.26 to 1.53] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.302 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Ischemic heart disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.41 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.01 [0.51 to 1.99] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.982 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Mesenteric trombosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.53 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.80 [0.24 to 2.62] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.709 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Stroke \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">20 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.76 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.57 [0.28 to 1.17] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.122 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Dysrhythmia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.53 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.25 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.48 [0.12 to 1.92] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.289 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Peripheral arteriopathy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.09 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.89 [0.17 to 20.88] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.596 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Infection</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">27 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2.37 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.34 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.56 [0.30 to 1.05] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.065 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Tumor</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.79 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.27 [0.53 to 3.00] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.592 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Sudden death</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.23 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.59 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.29 [0.65 to 2.57] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.470 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Cachexia</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.88 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.57 [0.21 to 1.58] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.276 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Death from other causes</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">20 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.76 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.09 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.62 [0.31 to 1.24] \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.172 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1383025.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "*" "nota" => "<p class="elsevierStyleNotepara" id="npar0015"><span class="elsevierStyleItalic">P</span> value by the log-rank test.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Primary outcome. Mortality (ITT).</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:22 [ 0 => array:3 [ "identificador" => "bib0115" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High-efficiency posdilution online hemodiafiltration reduce all-cause mortality in hemodialysis patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Maduell" 1 => "F. Moreso" 2 => "M. Pons" 3 => "R. Ramos" 4 => "J. Mora-Macià" 5 => "J. Carreras" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1681/ASN.2012080875" "Revista" => array:6 [ "tituloSerie" => "J Am Soc Nephrol" "fecha" => "2013" "volumen" => "24" "paginaInicial" => "487" "paginaFinal" => "497" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23411788" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0120" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hemodialysis (HEMO) study group: effect of dialysis dose and membrane flux in maintenance hemodialysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Eknoyan" 1 => "G.J. Beck" 2 => "A.K. Cheung" 3 => "J.T. Daugirdas" 4 => "T. Greene" 5 => "J.W. Kusek" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa021583" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2002" "volumen" => "347" "paginaInicial" => "2010" "paginaFinal" => "2019" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12490682" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0125" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Membrane Permeability Outcome (MPO) study group. Effect of membrane permeability on survival of hemodialysis patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Locatelli" 1 => "A. Martin-Malo" 2 => "T. Hannedouche" 3 => "A. Loureiro" 4 => "M. Papadimitriou" 5 => "V. Wizemann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1681/ASN.2008060590" "Revista" => array:6 [ "tituloSerie" => "J Am Soc Nephrol" "fecha" => "2009" "volumen" => "20" "paginaInicial" => "645" "paginaFinal" => "654" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19092122" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0130" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mortality and cardiovascular events in online-hemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish Online Haemodiafiltration study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Ok" 1 => "G. Asci" 2 => "H. Toz" 3 => "E.S. Ok" 4 => "F. Kircelli" 5 => "M. Yilmaz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ndt/gfs407" "Revista" => array:7 [ "tituloSerie" => "Nephrol Dial Transplant" "fecha" => "2013" "volumen" => "28" "paginaInicial" => "192" "paginaFinal" => "202" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23229932" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0735109712030409" "estado" => "S300" "issn" => "07351097" ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0135" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intention-to-treat issues" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J. Higgins" 1 => "S. Green" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:4 [ "titulo" => "Cochrane collaboration. Cochrane handbook for systematic reviews on interventions" "fecha" => "2008" "editorial" => "Cochrane Collaboration" "editorialLocalizacion" => "London" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0140" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The effects of excluding patients from the analysis in randomized clinical trials: meta-epidemiological study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Nuesch" 1 => "S. Trelle" 2 => "S. Reichenbach" 3 => "A.W.S. Rutjes" 4 => "E. Bürgi" 5 => "M. Scherer" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "BMJ" "fecha" => "2009" "volumen" => "339" "paginaInicial" => "b3244" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19736281" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0145" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Modified intention to treat reporting in randomised controlled trials: systematic review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "I. Abraha" 1 => "A. Montedori" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "BMJ" "fecha" => "2010" "volumen" => "340" "paginaInicial" => "c2697" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20547685" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0150" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.P.C. Grooteman" 1 => "M.A. van den Dorpel" 2 => "M.L. Bots" 3 => "E.L. Penne" 4 => "N.C. van der Weerd" 5 => "A.H.A. Mazairac" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Am Soc Nephrol" "fecha" => "2012" "volumen" => "23" "paginaInicial" => "1083" "paginaFinal" => "1096" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0155" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The issue of studying the effect of interventions in renal replacement therapy to what extend may web be deceived by selection and competiting risk?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "K.J. Jager" 1 => "V.S. Stel" 2 => "C. Zoccali" 3 => "C. Wanner" 4 => "F.W. Dekker" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ndt/gfq540" "Revista" => array:6 [ "tituloSerie" => "Nephrol Dial Transplant" "fecha" => "2010" "volumen" => "25" "paginaInicial" => "3836" "paginaFinal" => "3839" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20833688" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0160" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "When do we need competing risk methods for survival analysis in nephrology?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Noordzij" 1 => "K. Leffondré" 2 => "K.J. van Stralen" 3 => "C. Zoccali" 4 => "F.W. Dekker" 5 => "K.J. Jager" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ndt/gft355" "Revista" => array:6 [ "tituloSerie" => "Nephrol Dial Transplant" "fecha" => "2013" "volumen" => "28" "paginaInicial" => "2670" "paginaFinal" => "2677" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23975843" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0165" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Design and patient characteristics of ESHOL study: postdilution on-line hemodiafiltration versus hemodialysis, a Catalonian prospective randomised study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Maduell" 1 => "F. Moreso" 2 => "M. Pons" 3 => "R. Ramos" 4 => "J. Mora-Macià" 5 => "J. Carreras" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Nephrol" "fecha" => "2011" "volumen" => "24" "paginaInicial" => "196" "paginaFinal" => "202" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20602331" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0170" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "ESHOL study. A randomized study to evaluate survival in patients undergoing on-line HDF. [revised 27 Feb 2014]. Disponible en: <a href="http://clinicaltrials.gov/ct2/show/NCT00694031">http://clinicaltrials.gov/ct2/show/NCT00694031</a>." ] ] ] 12 => array:3 [ "identificador" => "bib0175" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Modeling survival data: extending the Cox model (statistics for biology and health)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "T. Therneau" 1 => "P. Grambsch" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2000" "editorial" => "Springer-Verlag" "editorialLocalizacion" => "New York Inc" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0180" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A proportional hazards model for the subdistribution of a competing risk" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J. Fine" 1 => "R. Gray" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Am Stat Assoc" "fecha" => "1999" "volumen" => "94" "paginaInicial" => "496" "paginaFinal" => "509" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0185" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Class of K-sample tests for comparing the cumulative incidence of a competing risk" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "R.A. Gray" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ann Stat" "fecha" => "1988" "volumen" => "16" "paginaInicial" => "1141" "paginaFinal" => "1154" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0190" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "What is meant by intention to treat analysis? Survey of published randomised controlled trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S. Hollis" 1 => "F. Campbell" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "BMJ" "fecha" => "1999" "volumen" => "319" "paginaInicial" => "670" "paginaFinal" => "674" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10480822" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0195" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness of antidepressants. Meta-analysis of dose–effect relationships in randomised clinical trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "P. Bollini" 1 => "S. Pampallona" 2 => "G. Tibaldi" 3 => "B. Kupelnick" 4 => "C. Munizza" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Psychiatry" "fecha" => "1999" "volumen" => "174" "paginaInicial" => "297" "paginaFinal" => "300" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10533547" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0200" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Convective therapies versus low-flux hemodialysis for chronic kidney failure: a meta-analysis of randomized controlled trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "P. Susantitaphong" 1 => "M. Siribamrungwong" 2 => "B.L. Jaber" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ndt/gft396" "Revista" => array:6 [ "tituloSerie" => "Nephrol Dial Transplant" "fecha" => "2013" "volumen" => "28" "paginaInicial" => "2859" "paginaFinal" => "2874" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24081858" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0205" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Convective versus diffusive dialysis therapies for chronic kidney failure: an update systematic review of randomized controlled trials" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I. Nistor" 1 => "S.C. Palmer" 2 => "J.C. Craig" 3 => "V. Saglimbene" 4 => "M. Vecchio" 5 => "A. Covic" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.ajkd.2013.12.004" "Revista" => array:6 [ "tituloSerie" => "Am J Kidney Dis" "fecha" => "2014" "volumen" => "63" "paginaInicial" => "954" "paginaFinal" => "967" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24434188" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0210" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of hemodiafiltration or hemofiltration compared with hemodialysis on mortality and cardiovascular disease in chronic kidney failure: a systematic review and meta-analysis of randomized trials" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.Y. Wang" 1 => "T. Ninomiya" 2 => "A. Al-Kahwa" 3 => "V. Perkovic" 4 => "M.P. Gallagher" 5 => "C. Hawley" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.ajkd.2014.01.435" "Revista" => array:6 [ "tituloSerie" => "Am J Kidney Dis" "fecha" => "2014" "volumen" => "63" "paginaInicial" => "968" "paginaFinal" => "978" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24685515" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0215" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EUDIAL – an official ERA-EDTA Working Group, clinical evidence on hemodiafiltration: a systematic review and a meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I. Mostovaya" 1 => "P.J. Blankestijn" 2 => "M.L. Bots" 3 => "A. Covic" 4 => "A. Davenport" 5 => "M.P.C. Grooteman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Semin Dial" "fecha" => "2014" "volumen" => "27" "paginaInicial" => "119" "paginaFinal" => "127" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24738146" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0735109707038739" "estado" => "S300" "issn" => "07351097" ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0220" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EUDIAL – an official ERA-EDTA Working Group: online haemodiafiltration: definition, dose quantification and safety revisited" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.E. Tattersall" 1 => "R.A. Ward" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ndt/gfs530" "Revista" => array:6 [ "tituloSerie" => "Nephrol Dial Transplant" "fecha" => "2013" "volumen" => "28" "paginaInicial" => "542" "paginaFinal" => "550" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23345621" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack275989" "titulo" => "Acknowledgments" "texto" => "<p id="par0120" class="elsevierStylePara elsevierViewall">The ESHOL study has had the endorsement of the Catalan Society of Nephrology. This study was partly supported by grants from Fresenius Medical Care and Gambro through the <span class="elsevierStyleGrantSponsor" id="gs1">Catalan Society of Nephrology</span>.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003600000002/v4_201703310238/S2013251416000298/v4_201703310238/en/main.assets" "Apartado" => array:4 [ "identificador" => "42660" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003600000002/v4_201703310238/S2013251416000298/v4_201703310238/en/main.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251416000298?idApp=UINPBA000064" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 9 | 6 | 15 |
2024 October | 87 | 44 | 131 |
2024 September | 64 | 32 | 96 |
2024 August | 71 | 55 | 126 |
2024 July | 66 | 26 | 92 |
2024 June | 83 | 37 | 120 |
2024 May | 82 | 31 | 113 |
2024 April | 84 | 50 | 134 |
2024 March | 59 | 42 | 101 |
2024 February | 84 | 45 | 129 |
2024 January | 56 | 37 | 93 |
2023 December | 42 | 46 | 88 |
2023 November | 94 | 59 | 153 |
2023 October | 83 | 22 | 105 |
2023 September | 67 | 21 | 88 |
2023 August | 85 | 31 | 116 |
2023 July | 77 | 37 | 114 |
2023 June | 69 | 21 | 90 |
2023 May | 66 | 35 | 101 |
2023 April | 48 | 40 | 88 |
2023 March | 85 | 30 | 115 |
2023 February | 50 | 20 | 70 |
2023 January | 41 | 28 | 69 |
2022 December | 85 | 42 | 127 |
2022 November | 76 | 34 | 110 |
2022 October | 74 | 54 | 128 |
2022 September | 37 | 32 | 69 |
2022 August | 49 | 57 | 106 |
2022 July | 32 | 52 | 84 |
2022 June | 37 | 49 | 86 |
2022 May | 78 | 40 | 118 |
2022 April | 74 | 70 | 144 |
2022 March | 91 | 47 | 138 |
2022 February | 94 | 49 | 143 |
2022 January | 74 | 37 | 111 |
2021 December | 41 | 44 | 85 |
2021 November | 43 | 36 | 79 |
2021 October | 49 | 47 | 96 |
2021 September | 43 | 31 | 74 |
2021 August | 38 | 62 | 100 |
2021 July | 42 | 45 | 87 |
2021 June | 72 | 56 | 128 |
2021 May | 34 | 43 | 77 |
2021 April | 89 | 25 | 114 |
2021 March | 51 | 33 | 84 |
2021 February | 50 | 25 | 75 |
2021 January | 43 | 20 | 63 |
2020 December | 40 | 19 | 59 |
2020 November | 43 | 21 | 64 |
2020 October | 33 | 17 | 50 |
2020 September | 27 | 14 | 41 |
2020 August | 44 | 12 | 56 |
2020 July | 38 | 10 | 48 |
2020 June | 32 | 18 | 50 |
2020 May | 41 | 14 | 55 |
2020 April | 31 | 17 | 48 |
2020 March | 27 | 14 | 41 |
2020 February | 32 | 16 | 48 |
2020 January | 40 | 25 | 65 |
2019 December | 50 | 28 | 78 |
2019 November | 59 | 31 | 90 |
2019 October | 24 | 10 | 34 |
2019 September | 27 | 20 | 47 |
2019 August | 22 | 13 | 35 |
2019 July | 50 | 19 | 69 |
2019 June | 25 | 15 | 40 |
2019 May | 24 | 18 | 42 |
2019 April | 72 | 21 | 93 |
2019 March | 52 | 20 | 72 |
2019 February | 29 | 17 | 46 |
2019 January | 46 | 27 | 73 |
2018 December | 140 | 46 | 186 |
2018 November | 272 | 20 | 292 |
2018 October | 262 | 26 | 288 |
2018 September | 71 | 17 | 88 |
2018 August | 50 | 18 | 68 |
2018 July | 54 | 14 | 68 |
2018 June | 47 | 13 | 60 |
2018 May | 55 | 14 | 69 |
2018 April | 45 | 7 | 52 |
2018 March | 42 | 8 | 50 |
2018 February | 34 | 9 | 43 |
2018 January | 40 | 6 | 46 |
2017 December | 44 | 8 | 52 |
2017 November | 66 | 16 | 82 |
2017 October | 41 | 9 | 50 |
2017 September | 45 | 10 | 55 |
2017 August | 24 | 8 | 32 |
2017 July | 47 | 17 | 64 |
2017 June | 56 | 8 | 64 |
2017 May | 59 | 14 | 73 |
2017 April | 51 | 10 | 61 |
2017 March | 36 | 11 | 47 |
2017 February | 58 | 11 | 69 |
2017 January | 37 | 9 | 46 |
2016 December | 55 | 8 | 63 |
2016 November | 75 | 17 | 92 |
2016 October | 82 | 9 | 91 |
2016 September | 106 | 2 | 108 |
2016 August | 173 | 6 | 179 |
2016 July | 194 | 16 | 210 |
2016 June | 118 | 0 | 118 |
2016 May | 178 | 0 | 178 |
2016 April | 121 | 0 | 121 |
2016 March | 52 | 0 | 52 |